Clive Beddoe is the Chairman of our Board of Directors and head of the Compensation Committee. Mr. Beddoe is the CEO and Chairman of Hanover Holding and Investment Company, which he founded in 1977. Mr. Beddoe was the Founder and CEO of WestJet Airlines Ltd. from 1995 until 2007, and the Chairman of the Board of Directors of WestJet from 1995-2019. Mr. Beddoe served on the board of Alberta Investment Management Corporation (AIMco) from 2008-2014. Mr. Beddoe has been the recipient of honorary degrees from the University of Calgary and Wilfred Laurier University and was appointed the 2010-2011 Jarislowsky Resident Fellow in Business Management at the Haskayne School of Business at the University of Calgary. Mr. Beddoe was inducted into the Canadian Business Hall of Fame in 2012 and the Calgary Business Hall of Fame in 2013.
CHAIRMAN OF THE BOARD OF DIRECTORS
DIRECTOR AND CHIEF SCIENTIFIC OFFICER
Eric Brouwer, PhD is the Chief Scientific Officer of SQI Diagnostics, Inc. and has served in that position since October 2017. From April 2015 to May 2017, Mr. Brouwer was the Chief Scientific Officer of Trinity Biotech plc and then CEO of its subsidiary, Fiomi. From 2003 to 2015, Mr. Brouwer held various positions in Research and Development at Abbott Point of Care, including Senior Manager Research and Director of Assay Research and Development. While at Abbott, Mr. Brouwer developed and help launch a number of point of care diagnostics products, was the recipient of two divisional President’s Awards (2006, 2008) and the prestigious Chairman’s Award in 2007 and served as a member of the Abbott Scientific Governing Board. Mr. Brouwer also was a member of the Ottawa Life Sciences Council 2013 to 2014. From 2000 to 2003, Mr. Brouwer was a Senior Scientist at the point-of-care diagnostic innovator and industry leader i-STAT, prior to the acquisition of i-STAT by Abbott. Mr. Brouwer holds three U.S. patents and has authored over 30 peer-reviewed journal articles. Mr. Brouwer holds multiple degrees in chemistry from Queen’s University (BSc(Hons)), University of British Columbia (MSc) and Carleton University (PhD) and a post-doctoral fellowship at the University of Durham (UK).
Gerald R. Connor
Gerald R. Connor is a member of our Board of Directors. Mr. Connor is currently Chairman of Cumberland Private Wealth Management Inc., which he founded in in 1997. From 1977 to 1997, Mr. Connor was co-Founder and President of Connor, Clark & Company. During this period, Mr. Connor was also co-Founder and Chairman of Connor, Clark & Lunn and 20/20 Investment Management. Mr. Connor is currently a trustee of Allied Properties Real Estate Investment Trust which he co-founded in 1998 and serves as Chair of the audit committee. Mr. Connor graduated with a BA from DePauw University.
Wilmot L. Matthews
Wilmot L. Matthews is a member of our Board of Directors since April 2015. Mr. Matthews is the President of private investment company Marjad Inc., which he founded in 1995. Mr. Matthews is also a member of the Investment Advisory Committee of Imperial Capital. Mr. Matthews served as Vice Chairman of Nesbitt Burns, formerly known as Nesbitt Thomson, a wholly-owned subsidiary of The Bank of Montreal, from 1994-1996. From 1963-1994, Mr. Matthews served as a fund analyst, fund manager and co-head of corporate and government services for Fry & Company Limited, prior to its merger with Nesbitt Thomson. Mr. Matthews received his Bachelor of Arts in Math, Physics and Chemistry from the University of Toronto in 1958, and both his Master of Business Administration degree from the London School of Economics in Business Administration and his Master of Science in Economics from the London School of Economics in London, England in 1964.
Eric Zwisler is a member of our Board of Directors since June 2018. Mr. Zwisler is Chairman of the Board of the La Jolla Institute for Immunology, one of the world’s top-five biomedical research institutes focused on understanding the immune response to infectious agents and cancers, since 2019. From 2013 – 2018 Mr. Zwisler was the Chairman of Cardinal Health China, a subsidiary of Cardinal Health (NYSE: CAH). He is also Chairman of the Board of ITG, a private sustainable insect protein business in London and serves as board member to several other organizations. From 2002-2014, Mr. Zwisler served as a board member of the International Federation of Pharmaceutical Wholesalers, serving as Chairman of the Board 2012 to 2014. Mr. Zwisler is a graduate of Carroll College (BA Economics 1980) and the University of Michigan (MBA 1982).
DIRECTOR AND CHIEF EXECUTIVE OFFICER
Mr Morris is currently the CEO of SQI Diagnostics, a position he held since October 2021, as well as from October 2013 to March 2020. Andrew Morris has been a member of our Board of Directors since October 2013. From 2004-2013, Mr. Morris was the Chief Financial Officer of SQI Diagnostics. Mr. Morris was Managing Partner, CFO and COO of ATWILL Medical Solutions LP. From 2001 to 2004, Mr. Morris was VP Mergers and Acquisitions of the Corporate Finance Life Sciences group at Ernst & Young. From 1999 to 2001, he was Director Finance at Norigen Communications. Mr. Morris was a staff scientist with the rank of Captain at the Defence and Civil Institute of Environmental Medicine, Canada from 1988 to 1999. Mr. Morris earned his Honours Bachelor of Science degree from the University of Western Ontario in 1988, a Master’s of Science degree from the Faculty of Medicine at the University of Toronto in 1996, and a Master’s of Business Administration degree from the Rotman School of Management at the University of Toronto in 1998.
Claude Ricks is a member of our Board of Directors and head of the Audit Committee since 2015. Mr. Ricks is a Managing Partner of Level5 Strategy since January 2017. From 2014-2016, Mr. Ricks was COO of gshift. Mr. Ricks was President and CEO of SQI Diagnostics from 2004-2013 and Board Chairman from June 2013-2014. From 1998-2002, Mr. Ricks was VP of Revenue for Solect Technology. Mr. Ricks is a graduate of Western University and earned his Bachelor of Science degree in Chemistry in 1979.